Results 31 to 40 of about 16,238 (237)

Inflammatory residual risk. An emerging target to reduce cardiovascular disease [PDF]

, 2018
Cardiovascular Residual Risk and Cardiovascular ...
Presta, Vivianne, Volpe, Massimo
core   +1 more source

Rilonacept and canakinumab [PDF]

British Journal of Clinical Pharmacology, 2011
Two new orphan medicines, rilonacept [1, 2] (Regeneron®) and canakinumab [3, 4] (Ilaris®), are indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS occur in a group of rare, inherited, inflammatory diseases where patients have a mutation in the NLRP3 (nucleotide-binding domain, leucine-rich family, pyrin domain-containing-
Eline A, Dubois, Robert, Rissmann, Adam F, Cohen   +2 more
openaire   +2 more sources

The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. [PDF]

, 2020
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed.
Ballas, Samir K
core   +1 more source

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

BMC Musculoskeletal Disorders, 2011
Background Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA).
Arulmani Udayasankar, Preiss Ralph, Krammer Gerhard, Sebba Anthony, Beaulieu Andre, Durez Patrick, Gomez-Reino Juan, Alten Rieke, Widmer Albert, Gitton Xavier, Kellner Herbert   +10 more
doaj   +1 more source

Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome

Pediatric Rheumatology Online Journal, 2019
Background Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1).
Abdulkadir A. Elmi, Karen Wynne, Iek L. Cheng, Despina Eleftheriou, Helen J. Lachmann, Philip N. Hawkins, Paul Brogan   +6 more
doaj   +1 more source

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): An open-label, phase II study [PDF]

, 2016
OBJECTIVE: To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1β antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome ...
Abrams, Ken, Bhansali, Suraj G., Cattalini, Marco, Davis, Nicole, Gattorno, Marco, Lachmann, Helen J., Martini, Alberto, Obici, Laura, Speziale, Antonio, Tormey, Vincent   +9 more
core   +1 more source

Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

International Journal of Immunopathology and Pharmacology, 2021
Introduction The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to ...
Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Filippo Urso, Francesca Greco, Maria V Mauro, Valeria Vangeli   +6 more
doaj   +1 more source

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? [PDF]

, 2016
Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are
Alvaro, S., Berardicurti, O., Carubbi, F., CICCIA, Francesco, Cipriani, P., Di Benedetto, P., Giacomelli, R., GUGGINO, Giuliana, Liakouli, V., Ruscitti, P., TRIOLO, Giovanni   +10 more
core   +1 more source

IL-1β inhibition in cardiovascular complications associated to diabetes mellitus [PDF]

, 2017
Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of all diagnosed cases of diabetes.
Carraro, Raffaele, Lorenzo, Óscar, Peiró, Concepción, Sánchez-Ferrer, Carlos F.   +3 more
core   +2 more sources

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

Pediatric Rheumatology Online Journal, 2023
Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval.
Gülşah Kavrul Kayaalp, Şengül Çağlayan, Fatma Gül Demirkan, Vafa Guliyeva, Gülçin Otar Yener, Kübra Öztürk, Ferhat Demir, Semanur Özdel, Mustafa Çakan, Hafize Emine Sönmez, Betül Sözeri, Nuray Aktay Ayaz   +11 more
doaj   +1 more source